Skip to main content
. Author manuscript; available in PMC: 2017 Jul 18.
Published in final edited form as: Cancer Immunol Immunother. 2011 Jan 26;60(5):629–638. doi: 10.1007/s00262-011-0970-1

Fig. 7.

Fig. 7

Proposed tumor interaction with DOTAP enantiomers. In vitro (R)- and (S)-DOTAP show little difference in stimulating BMDC, shown by the size of the straight arrows. Due to an unknown interaction between the immune system and the tumor, the presence of a tumor in the in vivo system amplified the difference between (R)-and (S)-DOTAP reflected by the size of the ribbon arrows. The distinction between the two formulations is further amplified via talk back from the tumor to the immune system